1 January 2023 in The Journal of Haemophilia Practice
Hereditary factor X (FX) deficiency is a rare autosomal recessive disorder that increases bleeding tendencies, ranging from epistaxis to intracranial haemorrhage (ICH), which can be life-threatening. Single factor concentrates are recommended for treating rare bleeding disorders; however, in India most people with FX deficiency are treated with fresh frozen plasma (FFP). We report a case of FX deficiency in a child with a history of intracranial bleeding who was found to have a novel mutation in the F10 gene. Although managed with weekly prophylactic FFP infusions, he continued to experience regular bleeding including two further instances of ICH. Other therapeutic options were unavailable or unaffordable. When the Indian Government added FEIBA to the essential drug list, a decision was made to try FEIBA prophylaxis to better manage his bleeding. In 2019, he was started on a weekly dose of FEIBA, 500 IU (20 IU/ kg and his prophylactic FFP transfusion regimen was stopped. His bleeding episodes started to reduce after two months of starting FEIBA prophylaxis. Over the last three years he has had only four minor bleeding episodes and has remained completely free of major bleeding. He is now able to receive home-based therapy and his prognosis can be considered to be improved. FEIBA may be a useful medicinal therapy for FX-deficient patients who suffer severe haemorrhagic episodes in countries where plasma-derived factor X (pdFX) is not available.
1 January 2024 in The Journal of Haemophilia Practice
DBDhrubajyoti Borpatragohain
Dhrubajyoti Borpatragohain
Introduction: Haemophilia presents challenges in joint pathology assessment, prompting exploration of point-of-care ultrasonography (POC-US) as a diagnostic tool. Aims: The study aimed to assess the diagnostic performance of point-of-care ultrasonography (POC-US) compared to magnetic resonance imaging (MRI) in detecting synovial hypertrophy, cartilage abnormality, and bony abnormality among people with haemophilia (PWH) treated at Assam Medical College Hospital. Methods: Forty-two PWH underwent POC-US and MRI for joint assessment. The POC-US and MRI imaging interpretation involved calculating diagnostic accuracy parameters for POC-US and MRI scores. This included sensitivity, specificity, positive predictive value, and negative predictive value. Results: POC-US demonstrated a sensitivity of around 97% and specificity of 92% for detecting synovial hypertrophy, while showing a sensitivity of 85% and specificity of 100% for bony abnormality. Cartilage abnormality assessment revealed a sensitivity of 55% and specificity of 100%. Knee joint involvement was observed in all patients, with 7% also exhibiting ankle joint pathology. Disease severity distribution showed 57% with severe hemophilia, 24% with moderate, and 19% with mild disease. Conclusion: Our study highlights the diagnostic potential of POC-US in haemophilia management, particularly in detecting synovial hypertrophy and bony abnormality. Challenges in assessing cartilage abnormality warrant further investigation. These findings contribute to the discourse on POC-US in haemophilia management, emphasising the need for continued research to elucidate its clinical relevance.
30 April 2025 in Indian Journal of Hematology and Blood Transfusion